Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Blackhawk Growth Corp C.BLR.WT


Primary Symbol: C.BLR Alternate Symbol(s):  BLRZF

Blackhawk Growth Corp. is a Canada-based investment holding company. The Company invests in equity and debt instruments of companies to generate positive returns for shareholders. It focuses on investing in multiple companies across a variety of sectors across North America. The Company has focused its investments on the health, cannabis and cannabidiol (CBD) industries, in both Canada and the United States.


CSE:BLR - Post by User

Post by mavericks2020on Sep 09, 2021 10:00am
122 Views
Post# 33830641

Another good news

Another good news

 

Blackhawk's Sac Pharma has August revenue of $460,000

 

2021-09-09 09:55 ET - News Release

 

Mr. Frederick Pels reports

BLACKHAWK GROWTH'S SAC PHARMA ANNOUNCES RECORD AUGUST REVENUE OF CDN$460,000 AND INCLUDES OPERATIONAL UPDATE

Blackhawk Growth Corp. has noted record unaudited revenue in the month of August for Sac Pharma Partners USA, its wholly owned subsidiary, of $460,000. Sac Pharma continues to show strong revenue growth. Revenue for the 8 months ended August 31, 2021 is a company record of CDN$1,842,000. Sac Pharma has also continued to show strong gross margins of greater than 80% and positive cash flow for the year to date. These results are due to increasing facility yields, and the strong demand for Sac Pharma's premium products.

Sac Pharma is also very excited to announce that the next of its proprietary strains, "Morada" has completed the R&D testing approvals and has shown very high producing yield. The robust profile, color and potency has enabled Sac Pharma to be able to have pre-sold the entire production run of the new Morado premium product.

"Blackhawk is thrilled with the operating results and the continued development of very desirable proprietary strains", states Frederick Pels, CEO of Blackhawk. "We are very happy to have such a strong brand in our portfolio of companies."

Sac Pharma is operating at near capacity and expansion planning has begun.

Sac Pharma's signature products include the coveted Black Truffle, White Truffle strains, along with Bacio and Gelato.

The Company cautions that figures for revenue and margin generated by Sac Pharma have not been audited and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited.

About Blackhawk Growth

Blackhawk is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods and MindBio Therapeutics.

Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.

<< Previous
Bullboard Posts
Next >>